Galena Biopharma

RayzeBio to Participate in Upcoming Investor Conferences in November 2023

Retrieved on: 
Monday, November 6, 2023
Conference, Galena Biopharma, Cancer, SAN

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company’s management team will participate in the following investor conferences in November 2023:

Key Points: 
  • SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company’s management team will participate in the following investor conferences in November 2023:
    Truist Securities BioPharma Symposium: Panel discussion on Wednesday, November 8 at 10:45 a.m.
  • Jefferies London Healthcare Conference: Presentation on Wednesday, November 15 at 12:00 p.m. GMT (7:00 a.m.
  • Evercore ISI HealthCONx Conference: Fireside chat on Thursday, November 30 at 10:00 a.m.
  • RayzeBio will also be participating in 1x1 investor meetings at these conferences.

Healthcare M&A Volume Falls in Q3:23, According to Acquisition Data from LevinPro HC

Retrieved on: 
Thursday, October 12, 2023
Hospital, Antibody, Acquisition, Health care, Research, Intelligence, United Kingdom, Centene Corporation, HC, EHealth, Biogen, Reata Pharmaceuticals, Danaher Corporation, Galena Biopharma, Circle Health, Eli Lilly, Medical device, Hospice, Abcam, Real estate investment trust, Bed, Patient, Housing, Retail, Pharmaceutical industry, Circle

NEW CANAAN, Conn., Oct. 12, 2023 /PRNewswire-PRWeb/ -- Health care merger and acquisition activity declined in the third quarter of 2023, dropping to 497 deals, according to new acquisition data from LevinPro HC. Activity in the third quarter was 16% lower than in the second quarter, when 598 transactions were announced. Compared with the third quarter of 2022, activity fell 19% in the third quarter of 2023.

Key Points: 
  • Health care merger and acquisition activity declined in the third quarter of 2023, dropping to 497 deals, according to new acquisition data from LevinPro HC.
  • NEW CANAAN, Conn., Oct. 12, 2023 /PRNewswire-PRWeb/ -- Health care merger and acquisition activity declined in the third quarter of 2023, dropping to 497 deals, according to new acquisition data from LevinPro HC.
  • "It seems like the macro headwinds have finally caught up to the healthcare M&A market," said Dylan Sammut, Editor of Health Care at Irving Levin Associates, which publishes M&A data on its LevinPro HC platform.
  • The company publishes research reports and newsletters and maintains databases on the healthcare and senior housing M&A markets.

Fortune Media and Great Place To Work Name Azzur Group to 2023 Best Workplaces in BioPharma, Ranking No. 17

Retrieved on: 
Monday, September 18, 2023
Azur, Biotechnology, Organization, Great Places, 100 Best Workplaces in Europe, Management, Nursing, Galena Biopharma

HATBORO, Pa., Sept. 18, 2023 /PRNewswire/ -- Great Place To Work® and Fortune magazine have selected Azzur Group for the 2023 Fortune Best Workplaces in BioPharma™ List .

Key Points: 
  • HATBORO, Pa., Sept. 18, 2023 /PRNewswire/ -- Great Place To Work® and Fortune magazine have selected Azzur Group for the 2023 Fortune Best Workplaces in BioPharma™ List .
  • Earning a spot means that Azzur Group is one of the best companies to work for in the country.
  • "We are incredibly appreciative of our excellent employees who make Azzur Group a great place to work," said Michael Khavinson , Chief Executive Officer, Azzur Group.
  • "Congratulations to the Best Workplaces in BioPharma," says Michael C. Bush, CEO of Great Place To Work.

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14

Retrieved on: 
Wednesday, September 13, 2023
Health, Technology, Genetics, Artificial Intelligence, Pharmaceutical, Biotechnology, OTCQB, Intelligence, Failure, Galena Biopharma, Bank statement, OTC, Pink sheet, Security (finance)

The Company’s common stock will be quoted on the Pink Sheets platform operated by OTC Markets Group Inc. (the “OTC”) and will commence trading on September 14, 2023 at the market open under the “KRBP” ticker symbol.

Key Points: 
  • The Company’s common stock will be quoted on the Pink Sheets platform operated by OTC Markets Group Inc. (the “OTC”) and will commence trading on September 14, 2023 at the market open under the “KRBP” ticker symbol.
  • The Company’s stock will be quoted on the OTC Pink® Open Market while it pursues an uplisting to the OTCQB exchange.
  • Kiromic remains committed to maintaining transparency with its shareholders.
  • While the reporting requirements are different on the OTC Pink Sheets, the Company will continue to file regular financial statements and provide updates consistent with Nasdaq requirements and past practices.

Unispace Group strengthens its life sciences offering by acquiring Bulb

Retrieved on: 
Thursday, August 17, 2023
BPE, Bulb, Growth, ARC, R, Center for Advanced Research and Technology, Galena Biopharma, Construction

LONDON, Aug. 17, 2023 /PRNewswire/ -- Global life sciences strategy, design, and construction firm, Unispace Life Sciences , has acquired UK laboratory and office fit-out specialist Bulb.

Key Points: 
  • LONDON, Aug. 17, 2023 /PRNewswire/ -- Global life sciences strategy, design, and construction firm, Unispace Life Sciences , has acquired UK laboratory and office fit-out specialist Bulb.
  • Bulb will operate as 'Unispace Life Sciences', part of the Unispace Group, with a highly experienced team fully dedicated to creating inspiring facilities, labs and workplaces for this sector.
  • CEO at Unispace Life Sciences, John O'Reilly said: "We are thrilled to welcome Bulb to our growing life sciences segment.
  • We look forward to beginning our new journey as Unispace Life Sciences and continuing to deliver inspiring and sustainable work environments that address the challenges today's life sciences businesses are facing."

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

Retrieved on: 
Tuesday, July 18, 2023
Exercise, Euroclear, Chapter Four, Extraordinary general meeting, Section 31, Swedish Companies Registration Office, Annual, Annual general meeting, BankID, Meeting, BTA, Article, Galena Biopharma, Person, Section 6 of the Canadian Charter of Rights and Freedoms, Address, Mannheimer, Acquisition, Centre for Sustainability and Environmental Management / Brunel Management Programme, Companies Act, CTI, Chapter 20 (Legion), Management, Post office box, Proxy, Holding company, Security (finance), Property management, Mail, Financial adviser, Car rental, Swedish

STOCKHOLM, July 18, 2023 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg.

Key Points: 
  • STOCKHOLM, July 18, 2023 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg.
  • 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Tuesday, 15 August 2023 at 10.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden.
  • Shareholders who wish to attend the meeting venue in person or by proxy must give notice in accordance with (A) above.
  • The completed and signed postal voting form may be sent by mail to Swedish Orphan Biovitrum AB (publ), "Extraordinary General Meeting", c/o Euroclear Sweden AB, P.O.

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

Retrieved on: 
Tuesday, July 18, 2023
Exercise, Euroclear, Chapter Four, Extraordinary general meeting, Section 31, Swedish Companies Registration Office, Annual, Annual general meeting, BankID, Meeting, BTA, Article, Galena Biopharma, Person, Section 6 of the Canadian Charter of Rights and Freedoms, Address, Mannheimer, Acquisition, Centre for Sustainability and Environmental Management / Brunel Management Programme, Companies Act, CTI, Chapter 20 (Legion), Management, Post office box, Proxy, Holding company, Security (finance), Property management, Mail, Financial adviser, Car rental, Swedish

STOCKHOLM, July 18, 2023 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg.

Key Points: 
  • STOCKHOLM, July 18, 2023 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg.
  • 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Tuesday, 15 August 2023 at 10.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden.
  • Shareholders who wish to attend the meeting venue in person or by proxy must give notice in accordance with (A) above.
  • The completed and signed postal voting form may be sent by mail to Swedish Orphan Biovitrum AB (publ), "Extraordinary General Meeting", c/o Euroclear Sweden AB, P.O.

Longeveron Welcomes Three New Prominent Board Members

Retrieved on: 
Tuesday, June 13, 2023
Bachelor of Science in Human Biology, FACC, University of Pennsylvania, MBA, City, University of London, Audible Magic, Thomas, Eli Lilly and Company, Berlin Packaging, Joseph M. Katz Graduate School of Business, University, Galena Biopharma, Carnegie Mellon University, Regenerative medicine, Boehringer Ingelheim, UCB, Magic, Book, Biotechnology, S.A, Wharton School of the University of Pennsylvania, Cranfield School of Management, Amgen, PCSA, Girolamo, San Francisco Playhouse, Portable ultrasound, Organizational behavior, SONO, Postgraduate education, WSTM, Aerospace engineering, American University in Cairo, Strategic Advisory Board for Intellectual Property Policy, Management, MD, Shareholder, Stanford University

MIAMI, June 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the election of three distinguished new directors to serve on the Longeveron Inc. Board of Directors. Wa’el Hashad, Khoso Baluch, and Jeffrey Pfeffer were elected at the Company’s Annual Meeting of Stockholders, held Friday June 9, 2023, and will serve until the 2026 Annual Meeting of Stockholders, or until their successors are duly elected. Concurrent with the election of the new Directors, the terms of Donald Soffer, Erin Borger, and Todd Girolamo to serve as directors expired.

Key Points: 
  • “We are very honored to welcome such prominent and experienced new members to our Board and look forward to their tremendous expertise, diverse experience, and counsel as we continue to advance our regenerative medicine toward critical milestones,” said Joshua M. Hare, MD, FACC, and Chairman of Longeveron.
  • We believe Longeveron is well positioned to realize the potential of Lomecel-B™, and we thank them for their dedication and service,” concluded Dr. Hare.
  • Summary biographies of the new directors are as follows:
    Wa’el Hashad has served as Chief Executive Officer of Longeveron since February, 2023.
  • He served as the Chairman of the Board for Da Volterra, a French privately held company, from December 2021 until November 2022.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CIR, CTIC, DFFN

Retrieved on: 
Tuesday, June 6, 2023
KKR, Galena Biopharma, Sale, Control, Advertising, CTI, Diffusion, Fraud, NYSE, Security (finance)

If you are a CIRCOR shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a CIRCOR shareholder, click here to learn more about your rights and options .
  • If you are a CTI BioPharma shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 21, 2023
Employment, CTIC, Galena Biopharma, CTI, Compensated emancipation, Pharmaceutical industry, Pension fund, Amend

The equity awards were approved on March 20, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved on March 20, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received options to purchase an aggregate of 124,000 shares of CTI BioPharma common stock.
  • The options will be issued upon each employee's grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date.
  • One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates.